ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The study will document the safety and efficacy of the combination of ARQ 501 and gemcitabine
in patients with treatment-naïve, unresectable, metastatic pancreatic adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)